The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients:the CHARISMA genetics study

Bhatt, Deepak L, Paré, Guillaume, Eikelboom, John W, Simonsen, Katy L, Emison, Eileen S, Fox, Keith A A, Steg, Ph Gabriel, Montalescot, Gilles, Bhakta, Nihar, Hacke, Werner, Flather, Marcus D, Mak, Koon-Hou, Cacoub, Patrice, Creager, Mark A, Berger, Peter B, Steinhubl, Steven R, Murugesan, Gurunathan, Mehta, Shamir R, Kottke-Marchant, Kandice, Lincoff, A Michael, Topol, Eric J and , CHARISMA Investigators (2012) The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients:the CHARISMA genetics study. European Heart Journal, 33 (17). pp. 2143-50. ISSN 0195-668X

Full text not available from this repository. (Request a copy)

Abstract

Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.

Item Type: Article
Uncontrolled Keywords: aryl hydrocarbon hydroxylases,atherosclerosis,female,genotype,hemorrhage,heterozygote,humans,ischemia,kaplan-meier estimate,male,middle aged,myocardial infarction,platelet aggregation inhibitors,polymorphism, genetic,stroke,thrombosis,ticlopidine
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:12
Last Modified: 21 Apr 2020 22:33
URI: https://ueaeprints.uea.ac.uk/id/eprint/46230
DOI: 10.1093/eurheartj/ehs059

Actions (login required)

View Item View Item